The Effect of Drugs on the Intestinal Microbiota in Crohn's Disease

• Published in: Biomedicines 2024-10, Vol.12 (10), p.2241
• Main Authors: Yang, Xue, Zhang, Yinghui, Gao, Caiping, Pan, Yan, Du, Shan, Xiao, Shiyu, Zhou, Zhou
• Format: Article
• Language: English
• Subjects: Azathioprine; Bacteria; Crohn's disease; Cytoskeleton; Drugs; fecal microbiota; Fecal microflora; Feces; Genes; Genomes; Inflammation; Infliximab; Intestinal microflora; Laboratories; mesalazine; Metabolism; metagenomic analysis; Metagenomics; Methionine; Microbiota; Monoclonal antibodies; Probiotics; Software; Species diversity; Statistical analysis; Tumor necrosis factor-α
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12102241

We took advantage of a single-center cross-sectional study to investigate the effect of different drugs on intestinal microbiota and function in Crohn's disease. We studied the difference in fecal microbiota of Crohn's disease patients treated with mesalazine, azathioprine, and infliximab, as well as untreated patients, by metagenome and screened for differential microbiota. Further, we investigated functional differences in intestinal microbiota among the four groups. Through metagenomic sequencing, we found that there was no difference between the four groups in ACE and Chao1 indices, but IFX and mesalazine improved species diversity and homogeneity compared to the untreated group, as evidenced by statistically significant differences in the Shannon index, Simpson index, and pielou_evenness. In addition, beta diversity suggested a difference between groups, but the difference was not significant. Non-parametric tests revealed differences between the four groups at the phylum level, class level, and genus level. Further analysis by LEfSe analysis revealed that the level of short-chain fatty acid-producing microbiota was increased in the treated groups, while there was no difference between the treated groups when compared to each other. Finally, the KEGG database and EggNOG database revealed that there were functional differences in intestinal microbiota among the four groups, including microbial metabolism pathway, cysteine and methionine metabolism pathway, cytoskeleton, etc. Conclusions: Mesalazine, azathioprine, and infliximab can all affect the intestinal microbiota and function in patients with Crohn's disease, and the drugs may alleviate intestinal inflammation in patients with Crohn's disease by modulating the intestinal microbiota.